UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 29, 2019

Tocagen Inc.
(Exact name of registrant as specified in its charter)

 
					
Delaware	 	001-38052	 	26-1243872	
(State or other jurisdiction
of incorporation)	 	(Commission
File Number)	 	(IRS Employer
Identification No.)	
		
4242 Campus Point Court, Suite 500
San Diego, California	 	92121	
(Address of principal executive offices)	 	(Zip Code)	
Registrant’s telephone number, including area code: (858) 412-8400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	 	Trading Symbol(s)	 	Name of each exchange on which registered	
Common Stock, par value
$0.001 per share	 	TOCA	 	The Nasdaq Global Select Market	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 29, 2019, Tocagen Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 4, 2019, the record date for the Annual Meeting, 23,270,962 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.
A total of 17,436,475 shares of the Company’s common stock were present at the Annual Meeting in person or by proxy, which represents approximately 75% of the shares of the Company’s common stock outstanding as of the record date for the Annual Meeting.
Proposal 1. Election of Directors.
The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

	Name	  	Votes For	 	  	Votes
Withheld	 	  	Broker
Non-Votes	 	
Franklin M. Berger	  	 	5,365,864	 	  	 	3,754,820	 	  	 	8,315,791	 		
Lori Kunkel, M.D.	  	 	7,720,648	 	  	 	1,400,036	 	  	 	8,315,791	 		
David Parkinson, M.D.	  	 	4,999,706	 	  	 	4,120,978	 	  	 	8,315,791	 		
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.
The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The final voting results are as follows:

Votes For	  	Votes Against	  	Abstention	  	Broker Non-Votes	
16,807,037	  	40,487	  	588,951	  	—	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	 		 	Tocagen Inc.	
				
Dated: May 31, 2019	 		 	By:	 	/s/ Mark Foletta	
	 		 		 	Mark Foletta	
	 		 		 	Executive Vice President, Chief Financial Officer